Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits

doi:10.3390/neurolint13020022

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

Neurol Int. 2021 May 19;13(2):207-223. doi: 10.3390/neurolint13020022.

Authors

Amnon A Berger¹, Emily R Sottosanti¹, Ariel Winnick^{2

3}, Jonathan Izygon², Kevin Berardino⁴, Elyse M Cornett⁵, Alan D Kaye⁵, Giustino Varrassi⁶, Omar Viswanath^{5

7

8

9}, Ivan Urits^{5

10}

Affiliations

¹ Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA 02115, USA.
² Soroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva 8400100, Israel.
³ School of Optometry, University of California, Berkeley, CA 94720, USA.
⁴ School of Medicine, Georgetown University, Washington, DC 20007, USA.
⁵ Department of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
⁶ Paolo Procacci Foundation, Via Tacito 7, 00193 Roma, Italy.
⁷ Department of Anesthesiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
⁸ Valley Anesthesiology and Pain Consultants-Envision Physician Services, Phoenix, AZ 85001, USA.
⁹ Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE 68124, USA.
¹⁰ Southcoast Health, Southcoast Health Physician Group Pain Medicine, North Dartmouth, MA 02747, USA.

Abstract

Multiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticosteroids for the suppression of relapses and injectable interferons. Recently, several modern therapies-including antibody therapy and oral agents-were approved as disease-modifying agents. Monomethyl fumarate (MMF, Bafiertam) is a recent addition to the arsenal available in the fight against MS and appears to be well-tolerated, safe, and effective. In this paper, we review the evidence available regarding the use of monomethyl fumarate (Bafiertam) in the treatment of relapsing-remitting MS.

Keywords: CNS plaques; autoimmune; corticosteroids; disability; disease-modifying agents.

Publication types

Review